Epinephrine Injection
Injection
To Be Discontinued Active (discontinuing) — Day 188
FDA shortage record
- Substance
- Epinephrine Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage form
- Injection
- Presentation
- Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10)
- Therapeutic category
- Cardiovascular, Endocrinology/Metabolism
- Package NDC
0409-4933-10- Initially posted
- 11/07/2025
- Days on shortage list
- 188
- Discontinued
- 11/07/2025
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 1 record for Epinephrine Injection
Why this shortage matters
Cardiovascular drugs manage heart failure, arrhythmias, hypertension, and coronary artery disease. Shortages can disrupt stable long-term therapy or create gaps in acute care where dosing consistency is essential to preventing cardiac events.
FDA therapeutic class: Cardiovascular, Endocrinology/Metabolism
Reason and context
Discontinuation of the manufacture of the drug
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 844-646-4398.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.